MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
Canopy Growth Corporation Total Liabilities 2011-2026 | CGC
Annual Total Liabilities Canopy Growth Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 430 M | 800 M | 1.68 B | 1.58 B | 3.2 B | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.2 B | 430 M | 1.54 B |
Quarterly Total Liabilities Canopy Growth Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 348 M | 334 M | 416 M | 430 M | 573 M | 723 M | 753 M | 800 M | 815 M | 1.34 B | 1.68 B | 1.58 B | 1.74 B | 1.83 B | 1.98 B | 2.1 B | 2.18 B | 2.69 B | 3.2 B | 2.01 B | 1.42 B | 1.58 B | 1.68 B | - | - | - | 1.49 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.2 B | 334 M | 1.4 B |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
10.5 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
52.3 M | $ 5.51 | -0.36 % | $ 81.8 M | USA |
 |
Cronos Group
CRON
|
54.2 M | $ 2.73 | 2.25 % | $ 1.05 B |  Canada |
 |
Harrow Health
HROW
|
347 M | $ 32.96 | 6.8 % | $ 1.21 B | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
165 M | $ 2.66 | 4.31 % | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 23.48 | 2.09 % | $ 1.09 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.45 | -0.91 % | $ 1.99 B | Canada |
 |
Tilray
TLRY
|
977 M | $ 5.46 | 0.92 % | $ 3.37 B | Canada |
 |
Solid Biosciences
SLDB
|
52.5 M | $ 6.5 | 0.46 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
244 M | $ 3.56 | 2.59 % | $ 195 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 1.06 | -0.93 % | $ 1.32 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.13 | 5.61 % | $ 108 M | Canada |
 |
cbdMD
YCBD
|
3.19 M | $ 0.78 | 4.14 % | $ 3.14 M | USA |
 |
Evolus
EOLS
|
249 M | $ 6.45 | -2.12 % | $ 416 M | USA |
 |
Sundial Growers
SNDL
|
235 M | $ 1.47 | 2.08 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 8.37 | 2.7 % | $ 429 M | USA |
 |
Veru
VERU
|
11.5 M | $ 2.22 | 2.3 % | $ 32.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23.7 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
173 M | $ 23.37 | -0.3 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
7.49 M | $ 7.21 | 0.56 % | $ 285 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.71 | 6.32 % | $ 35.5 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
22.5 B | $ 16.46 | -0.78 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
11.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
20.2 M | $ 0.81 | -1.24 % | $ 29.1 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
8.26 M | $ 0.76 | 7.69 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
10.8 M | $ 2.11 | 1.44 % | $ 24.4 M | USA |